Our COVID19 phase 2 clinical trial for our lead product, rhu-pGSN, has begun.

Share on facebook
Share on twitter
Share on linkedin

May 17, 2011: BioAegis Therapeutics Signs Exclusive Option for Human Protein in Clinical Development

Plasma Gelsolin Could Hold the Key to the Body’s Ability to Localize Inflammation

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(May 17, 2011) BioAegis Therapeutics, Inc. announced today that it has entered into an Exclusive Option Agreement with Brigham and Women’s Hospital for technology based on research of Dr. Thomas Stossel, Director, Translational Medicine at Brigham and Women’s Hospital, and American Cancer Society Professor of Medicine, Harvard Medical School and collaborators at Massachusetts General Hospital, University of Pennsylvania, Beth Israel Deaconess Medical Center and BloodCenter of Wisconsin. This exclusive option to a worldwide license encompasses therapeutic and diagnostic uses of the technology for human and animal applications.